J Nephropathol. 2017;6(1):25-29.
doi: 10.15171/jnp.2017.05
PMID: 28042550
PMCID: PMC5106879
Scopus id: 84992314129
  Abstract View: 2839
  PDF Download: 835

Original Article

Pure red cell aplasia due to antibody against erythropoietin in hemodialysis patients

Maryam Rahbar 1, Zahra Chitsazian 2 * , Firoozeh Abdoli 2, Seyed-Masoud Moeini Taba 2, Hosein Akbari 3

1 Department of Nephrology, Tehran University of Medical Sciences, Tehran, Iran
2 Department of Internal Medicine, Kashan University of Medical Sciences, Kashan, Iran
3 Departement of Biostatics and Epidemiology, School of Public Health, Kashan University of Medical Sciences, Kashan, Iran
Corresponding author: Zahra Chitsazian. Department of Internal Medicine, Kashan University of Medical Sciences, Kashan, Iran. Email: z_chitsazian@yahoo.com

Abstract

Background: Anemia is a common complication of chronic renal failure due to reduce erythropoietin production by kidneys. Anemia treated with recombinant human erythropoietin (rHu-EPO). Pure red cell aplasia (PRCA) due to antibody productionagainst rHu-EPO is a rare but major complication of this drug.

Objectives: The aim of this study was to determine the prevalence of PRCA due to antibodies in dialysis patients with resistant anemia who received erythropoietin.

Patients and Methods: We studied 128 under maintenance hemodialysis patients more than 3 month in Kashan. In patients with anemia who received erythropoietin with dose requirements based on weight and anemia and without any another cause for anemia, evaluate for PRCA and anti-rHu-EPO antibody level were measured by ELISA.

Results: In this research, 75 patients (58.6%) were male and 53 patients (41.4%) were female. The mean age of the patients was 59.05 ± 16.66 years. The result of analysis showed that 55 (43%) patients had anemia with hemoglobin level less than 10 mg/dL. Only 3 patients had PRCA and antibodies against erythropoietin in serum. There were no correlation between age, gender, cause of renal failure, hemodialysis duration, hemoglobin level, rHu-EPO dose and levels of anti-rHu-EPO antibody serum value.

Conclusions: The result of this study indicated that administration of rHu-EPO in dialysis patients afflicted to kidney failure may cause PRCA especially through intravenous injection. However, this change is not statistically significant.

Implication for health policy/practice/research/medical education:

Administration of erythropoietin in patients suffering from kidney failure particularly through the venous route increases the incidence of red blood cell aplasia. However, this increase was not statistically significant and this condition may occur due to any of the two methods venous or subcutaneous injection.

Please cite this paper as: Rahbar M, Chitsazian Z, Abdoli F Moeini Taba SM, Akbari H. Pure red cell aplasia due to antibody against erythropoietin in hemodialysis patients. J Nephropathol. 2017;6(1):25-29. DOI: 10.15171/jnp.2017.05.

First name
 
Last name
 
Email address
 
Comments
 
Security code


Article Viewed: 2839

Your browser does not support the canvas element.


PDF Downloaded: 835

Your browser does not support the canvas element.

First published online: 22 Aug 2016
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - FireFox Plugin)